Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by PoorOpinionon Feb 19, 2018 3:50pm
108 Views
Post# 27584046

RE:RE:RE:RE:RE:RE:100

RE:RE:RE:RE:RE:RE:100Maybe the refs you're looking for are in the review I linked to earlier, this one has rat data for both H2S and NO releasing NSAIDS which look to perform equally well.

Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastroin- testinal-sparing effects of novel NSAIDs in rats with compro- mised mucosal defence. PLoS ONE. 2012;7:e35196. 

https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.695.5587&rep=rep1&type=pdf





StrikingMoose wrote: I wasn't attacking your post and I appreciate the comparable market value. Even I had not looked back to see who had partnered with Nicox for naproxincod. I remain hopeful that despite the theoretical GI effects of NO showing a benefical effect that we will see similar rodent-human translation as they did. I tried looking for the pre-clinical naproxincod data and can't find the study in question. Wish I could because it's got some nice pictures/charts showing placebo/naproxen/naproxincod and while there was indeed less severe lesions they were still there. Wallace's new way of measuring for gastric damage as a formula of lesion size and amount is a better value to read IMO compared to size of lesions/ulcers as they did with naproxincod and gives a truer picture of what to expect.... I hope.

Great to see they were able to get a name like AstraZeneca to partner up and buy in. I am hoping that they've already been working some existing relationships in this pre-pivotal time to get some preliminary negotiations started.

I remain hopeful as well that there is some big money waiting on the sidelines watching this, waiting for the trial results to come back positive or not in order to take sizeable positions. I hope everyone had a fantastic family day weekend :)


Bullboard Posts